Literature DB >> 15106090

Measles outbreak epidemiology in the United States, 1993-2001.

Fuyuen Y Yip1, Mark J Papania, Susan B Redd.   

Abstract

To evaluate the extent of measles virus circulation and populations at risk in the United States, we reviewed measles outbreaks during 1993-2001. A total of 120 measles outbreaks, constituting 1804 outbreak-related cases, were reported during this period. The maximum outbreak size decreased from 233 cases in 1993-1995 to 119 cases in 1996-1998 and 15 cases in 1999-2001. The maximum outbreak duration decreased from 127 days in 1993-1995 to 65 days in 1999-2001. The majority of outbreaks resulted from documented spread from an internationally imported case (42%) or had a strain of measles virus not endemic in the United States (12%). Outbreaks in which adults were the predominant age group affected accounted for 35% of all outbreaks, compared with 29% of outbreaks predominantly affecting preschool children, 30% predominantly affecting school-aged children and adolescents, and 6% with no predominant age group. The extremely limited size and duration of measles outbreaks indicates very high population immunity to measles and suggests that measles is no longer endemic in the United States.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15106090     DOI: 10.1086/379377

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles-mumps-rubella-II (MMR-II) vaccination.

Authors:  N Dhiman; I G Ovsyannikova; J E Ryan; R M Jacobson; R A Vierkant; V S Pankratz; S J Jacobsen; G A Poland
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

2.  Does the relative importance of MMR vaccine concerns differ by degree of parental vaccine hesitancy?: An exploratory study.

Authors:  Charitha Gowda; Sarah E Schaffer; Kristin Kopec; Arielle Markel; Amanda F Dempsey
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

3.  A pilot study on the effects of individually tailored education for MMR vaccine-hesitant parents on MMR vaccination intention.

Authors:  Charitha Gowda; Sarah E Schaffer; Kristin Kopec; Arielle Markel; Amanda F Dempsey
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

4.  Measles outbreaks affecting children in Jewish ultra-orthodox communities in Jerusalem.

Authors:  C Stein-Zamir; G Zentner; N Abramson; H Shoob; Y Aboudy; L Shulman; E Mendelson
Journal:  Epidemiol Infect       Date:  2007-04-16       Impact factor: 2.451

5.  Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.

Authors:  Hayley A Gans; Linda L Yasukawa; Phillip Sung; Barbara Sullivan; Ross DeHovitz; Susette Audet; Judy Beeler; Ann M Arvin
Journal:  J Infect Dis       Date:  2013-01-08       Impact factor: 5.226

6.  The role of vaccination coverage, individual behaviors, and the public health response in the control of measles epidemics: an agent-based simulation for California.

Authors:  Fengchen Liu; Wayne T A Enanoria; Jennifer Zipprich; Seth Blumberg; Kathleen Harriman; Sarah F Ackley; William D Wheaton; Justine L Allpress; Travis C Porco
Journal:  BMC Public Health       Date:  2015-05-01       Impact factor: 3.295

7.  Occurrence of measles in a country with elimination status: Amplifying measles infection in hospitalized children due to imported virus.

Authors:  HyeEun Eom; YoungJoon Park; JooWhee Kim; Jeong-Sun Yang; HaeJi Kang; Kisoon Kim; Byung Chul Chun; Ok Park; Jeong Ik Hong
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

8.  A Comparison of Postelimination Measles Epidemiology in the United States, 2009-2014 Versus 2001-2008.

Authors:  Amy Parker Fiebelkorn; Susan B Redd; Paul A Gastañaduy; Nakia Clemmons; Paul A Rota; Jennifer S Rota; William J Bellini; Gregory S Wallace
Journal:  J Pediatric Infect Dis Soc       Date:  2017-03-01       Impact factor: 3.164

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.